Journals / Haseki Tıp Bülteni / 2017 / Cilt: 55 - Sayı: 2

What Should Be the Prostate Specific Antigen Threshold for Prostate Biopsy?

Prostat Biyopsisinde Prostat Spesifik Antijen Eşik Değeri Ne Olmalıdır?

Pages
146–150
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Since prostate cancer was not detected in any patient with a PSA value of <3.6 ng/mL in our study, we suggest higher PSA threshold values in order to reduce unnecessary prostate biopsy procedures.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim:­ There is still uncertainty today regarding the prostate specific antigen (PSA) threshold for prostate biopsy.
📊
Key Findings & Data:Methods: We retrospectively evaluated medical records of 375 patients, who underwent 12-16-core transrectal ultrasound-guided prostate biopsy between September 2012 and November 2015.
💡
Conclusion & Impact:Conclusion: Since prostate cancer was not detected in any patient with a PSA value of <3.6 ng/mL in our study, we suggest higher PSA threshold values in order to reduce unnecessary prostate biopsy procedures.
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim:­ There is still uncertainty today regarding the prostate specific antigen (PSA) threshold for prostate biopsy. From this point of view, we aimed to investigate the PSA threshold for prostate biopsy in this study. Methods: We retrospectively evaluated medical records of 375 patients, who underwent 12-16-core transrectal ultrasound-guided prostate biopsy between September 2012 and November 2015. The patients were divided into three groups according to the PSA values: group 1: 2.5-4ng/mL, group 2: 4.1-10 ng/mL and group 3: >10 ng/ mL. Age, prostate volume, prostate cancer detection rate, Gleason score, the average core length and the core length obtained per cc of prostate volume were compared between the groups. Results: The mean age of the patients was 64.39±7.62 years and the mean cancer detection rate was 26.7%, namely 11.5% (3/26), 17.4% (43/247) and 52.9% (54/102) in the groups 1, 2 and 3, respectively. Prostate cancer was not detected in any patient with a PSA value of <3.6 ng/mL (n=13). Conclusion: Since prostate cancer was not detected in any patient with a PSA value of <3.6 ng/mL in our study, we suggest higher PSA threshold values in order to reduce unnecessary prostate biopsy procedures.

Özet

Amaç: Prostat biyopsisi için prostat spesifik antijen (PSA) eşik değerinin ne olması gerektiği konusunda belirsizlikler devam etmektedir. Çalışmamızda prostat biyopsisi için PSA eşik değerini belirlemeyi amaçladık. Yöntemler:­ Eylül 2012 - Kasım 2015 tarihleri arasında transrektal ultrason kılavuzluğunda 12-16 kor prostat biyopsisi yapılan 375 hastanın kayıtları retrospektif olarak analiz edildi. Hastalar PSA değerine göre üç gruba ayrıldı. Grup 1; 2,5-4 ng/mL, grup 2; 4,1-10 ng/mL ve grup 3; >10 ng/mL. Gruplarda; prostat volümleri, yaş, prostat kanser saptama oranları, gleason skorları, ortalama kor uzunlukları ve prostat cc'si başına alınan kor uzunlukları karşılaştırıldı. Bulgular: Kanser saptama oranı %26,7 idi. Hastaların yaş ortalaması 64,39±7,62 yıl idi. Gruplarda kanser saptama oranları sırasıyla %11,5 (3/26), %17,4 (43/247) ve % 52,9 (54/102) idi. PSA değeri 3,6 ng/mL'den küçük olan hiçbir hastada (n=13) prostat kanseri saptanmadı. Sonuç: Çalışmamızda PSA <3,6 ng/mL olan hiçbir hastada prostat kanseri saptanmadı. PSA eşik değerinin daha yukarı çekilmesi gereksiz prostat biyopsilerini azaltabilir.

🔖

Cite This Article

DELİKTAŞ, H., ŞAHİN, H. (2017). What Should Be the Prostate Specific Antigen Threshold for Prostate Biopsy?. Haseki Tıp Bülteni, Cilt: 55 - Sayı: 2, 146–150. https://ajindex.com/articles/204845

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29
  2. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8
  3. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61
  4. Schröder FH, van der Cruijsen-Koeter I, de Koning HJ, Vis AN, Hoedemaeker RF, Kranse R. Prostate cancer detection at low prostate specific antigen. J Urol 2000;163:806-12
  5. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997;277:1452-5
  6. Deliktas H, Sahin H, Cetinkaya M, Dere Y, Erdogan O, Baldemir E. Does core length taken per cc of prostate volume in prostate biopsy affect the diagnosis of prostate cancer? Clin Genitourin Cancer 2016;14:e387-91
  7. Obek C, Ozkan B, Tunc B, Can G, Yalcin V, Solok V. Comparison of 3 different methods of anesthesia before transrectal prostate biopsy: a prospective randomized trial. J Urol 2004;172:502-5 8. Stephenson AJ, Jones JS, Hernandez AV, Ciezki JP, Gong MC, Klein EA. Analysis of T1c prostate cancers treated at very low prostate-specific antigen levels. Eur Urol. 2009;55:610-6
  8. Heidenreich A, Bellmunt J, Bolla M, et al. [EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease]. Actas Urol Esp 2011;35:501-14
  9. Carter HB, Pearson JD. Prostate-specific antigen testing for early diagnosis of prostate cancer: formulation of guidelines. Urology 1999;54:780-6
  10. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level _____ or =4.0 ng per milliliter. N Engl J Med 2004;350:2239-46
  11. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1994;152:1831-6
  12. Albayrak S, Tanık S, Zengin K, et al. Which prostate spesific antigen level is important? Yeni Üroloji Dergisi 2014;9:38-43
  13. Esen HH, Avunduk MC. Prostat adenokarsinomlarında PSA değerlerinin Gleason Skor ve klinik evre ile ilişkisi. Genel Tıp Dergisi 2007;17:211-5
  14. Merrill RM, Weed DL, Feuer EJ. The lifetime risk of developing prostate cancer in white and black men. Cancer E